Abstract:Background Type 1 diabetes mellitus (T1DM) is caused by immune cell-mediated β-cell dysfunction. In recent decades, N6-methyladenosine (m6A) has attracted widespread attention in the scientific research field because it plays vital roles in the pathogenesis of immunity-related diseases, including autoimmune diseases. However, neither the m6A modification profile nor the potential role it plays in T1DM pathogenesis has been investigated to date. Materials and Methods An m6A mRNA epitranscriptomic microarray analysis was performed to analyze m6A regulator expression patterns and m6A methylation patterns in immune cells of T1DM patients (n=6) and healthy individuals (n=6). A bioinformatics analysis was subsequently performed to explore the potential biological functions and signaling pathways underlying T1DM pathogenesis. Furthermore, mRNA expression and m6A methylation levels were subsequently verified by qRT–PCR and methylated RNA immunoprecipitation–qPCR (MeRIP–qPCR), respectively, in the T1DM and healthy groups (n=6 per group). Results Among the multiple m6A regulators, METTL3 and IGF2BP2 had significantly downregulated expression, and YTHDC1 and HNRNPA2B1 had significantly upregulated expression in the T1DM group relative to the healthy group. The microarray analysis revealed 4247 differentially methylated transcripts, including 932 hypermethylated and 3315 hypomethylated transcripts, and 4264 differentially expressed transcripts, including 1818 upregulated transcripts and 2446 downregulated transcripts in the T1DM group relative to the healthy group. An association analysis between methylation and gene expression demonstrated that the expression of 590 hypermethylated transcripts was upregulated, and that of 1890 hypomethylated transcripts was downregulated. Pearson correlation analysis showed significant correlations between the expression levels of differentially expressed m6A regulators and the methylation levels of differentially methylated transcripts and significant correlations between the expression levels of differentially expressed m6A regulators and that of differentially expressed transcripts. Moreover, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses demonstrated that differentially methylated transcripts were involved in pathways related to immunity, including some closely associated with T1DM. Conclusions Our study presents m6A regulator expression patterns and m6A methylation patterns of immune cells in T1DM, showing that the m6A mark and m6A regulators are promising targets for T1DM diagnosis and treatment.

M6 A Mrna Methylation: Biological Features, Mechanisms, and Therapeutic Potentials in Type 2 Diabetes Mellitus.

M6a-Binding Proteins: the Emerging Crucial Performers in Epigenetics

M6a Methylation: A New Avenue for Control of the Development of Type 2 Diabetes Mellitus and its Complications

The emerging roles of N6-methyladenosine RNA methylation in human cancers

Rna N-6-Methyladenosine Methylation In Post-Transcriptional Gene Expression Regulation

N6-methyladenine RNA methylation epigenetic modification and diabetic microvascular complications

The role of m6A and m6Am RNA modifications in the pathogenesis of diabetes mellitus

N 6 -Methyladenosine Modification-Mediated Mrna Metabolism is Essential for Human Pancreatic Lineage Specification and Islet Organogenesis

M6a Epitranscriptomic Modification in Diabetic Microvascular Complications

The Emerging Molecular Mechanism of M6a Modulators in Tumorigenesis and Cancer Progression

The m6A methylation profiles of immune cells in type 1 diabetes mellitus

The role of m6A modification in the biological functions and diseases

The role of m 6 A modification in type 2 diabetes: a systematic review and integrative analysis

Insights into RNA N6-methyladenosine in Glucose and Lipid Metabolic Diseases and Their Therapeutic Strategies

Role Of M(6)A Rna Methylation In Cardiovascular Disease (Review)

285-OR: m6A carRNA Methylation Regulates Chromatin State and Transcription in Islets from Humans with Type 2 Diabetes

Role of m6A RNA methylation in cardiovascular disease (Review)

Emerging Role of M6a RNA Methylation in Nutritional Physiology and Metabolism

N6-methyladenosine-mediated Gene Regulation and Therapeutic Implications.

m6A mRNA Methylation Controls Functional Maturation in Neonatal Murine β-Cells

The Critical Roles of M6a Modification in Metabolic Abnormality and Cardiovascular Diseases